414 related articles for article (PubMed ID: 28601473)
1. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament light protein in blood predicts regional atrophy in Huntington disease.
Johnson EB; Byrne LM; Gregory S; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RA; Zetterberg H; Tabrizi SJ; Scahill RI; Wild EJ;
Neurology; 2018 Feb; 90(8):e717-e723. PubMed ID: 29367444
[TBL] [Abstract][Full Text] [Related]
3. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis.
Scahill RI; Zeun P; Osborne-Crowley K; Johnson EB; Gregory S; Parker C; Lowe J; Nair A; O'Callaghan C; Langley C; Papoutsi M; McColgan P; Estevez-Fraga C; Fayer K; Wellington H; Rodrigues FB; Byrne LM; Heselgrave A; Hyare H; Sampaio C; Zetterberg H; Zhang H; Wild EJ; Rees G; Robbins TW; Sahakian BJ; Langbehn D; Tabrizi SJ
Lancet Neurol; 2020 Jun; 19(6):502-512. PubMed ID: 32470422
[TBL] [Abstract][Full Text] [Related]
4. Mapping neurodegeneration across the Huntington's disease spectrum: a five-year longitudinal analysis of plasma neurofilament light.
Parkin GM; Thomas EA; Corey-Bloom J
EBioMedicine; 2024 Jun; 104():105173. PubMed ID: 38815362
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243
[TBL] [Abstract][Full Text] [Related]
6. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
[TBL] [Abstract][Full Text] [Related]
7. Associations between prognostic index scores and plasma neurofilament light in Huntington's disease.
Parkin GM; Corey-Bloom J; Long JD; Snell C; Smith H; Thomas EA
Parkinsonism Relat Disord; 2022 Apr; 97():25-28. PubMed ID: 35276585
[TBL] [Abstract][Full Text] [Related]
8. Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia.
Coarelli G; Darios F; Petit E; Dorgham K; Adanyeguh I; Petit E; Brice A; Mochel F; Durr A
Neurobiol Dis; 2021 Jun; 153():105311. PubMed ID: 33636389
[TBL] [Abstract][Full Text] [Related]
9. Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression.
Parkin GM; Corey-Bloom J; Snell C; Castleton J; Thomas EA
Parkinsonism Relat Disord; 2021 Jun; 87():32-38. PubMed ID: 33940564
[TBL] [Abstract][Full Text] [Related]
10. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
[TBL] [Abstract][Full Text] [Related]
11. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
Moss DJH; Pardiñas AF; Langbehn D; Lo K; Leavitt BR; Roos R; Durr A; Mead S; ; ; Holmans P; Jones L; Tabrizi SJ
Lancet Neurol; 2017 Sep; 16(9):701-711. PubMed ID: 28642124
[TBL] [Abstract][Full Text] [Related]
12. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.
Tabrizi SJ; Scahill RI; Durr A; Roos RA; Leavitt BR; Jones R; Landwehrmeyer GB; Fox NC; Johnson H; Hicks SL; Kennard C; Craufurd D; Frost C; Langbehn DR; Reilmann R; Stout JC;
Lancet Neurol; 2011 Jan; 10(1):31-42. PubMed ID: 21130037
[TBL] [Abstract][Full Text] [Related]
13. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Andreasson U; Zetterberg H; Blennow K;
JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
[TBL] [Abstract][Full Text] [Related]
14. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
15. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
Wild EJ; Boggio R; Langbehn D; Robertson N; Haider S; Miller JR; Zetterberg H; Leavitt BR; Kuhn R; Tabrizi SJ; Macdonald D; Weiss A
J Clin Invest; 2015 May; 125(5):1979-86. PubMed ID: 25844897
[TBL] [Abstract][Full Text] [Related]
16. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?
Niemelä V; Landtblom AM; Blennow K; Sundblom J
PLoS One; 2017; 12(2):e0172762. PubMed ID: 28241046
[TBL] [Abstract][Full Text] [Related]
17. Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children.
Byrne LM; Schultz JL; Rodrigues FB; van der Plas E; Langbehn D; Nopoulos PC; Wild EJ
Mov Disord; 2022 Jul; 37(7):1526-1531. PubMed ID: 35437792
[TBL] [Abstract][Full Text] [Related]
18. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease.
Rodrigues FB; Byrne LM; Tortelli R; Johnson EB; Wijeratne PA; Arridge M; De Vita E; Ghazaleh N; Houghton R; Furby H; Alexander DC; Tabrizi SJ; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
Sci Transl Med; 2020 Dec; 12(574):. PubMed ID: 33328328
[TBL] [Abstract][Full Text] [Related]
19. Plasma NfL as a prognostic biomarker for enriching HD-ISS stage 1 categorisation: a cross-sectional study.
Parkin GM; Thomas EA; Corey-Bloom J
EBioMedicine; 2023 Jul; 93():104646. PubMed ID: 37315450
[TBL] [Abstract][Full Text] [Related]
20. Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3.
Li QF; Dong Y; Yang L; Xie JJ; Ma Y; Du YC; Cheng HL; Ni W; Wu ZY
Mol Neurodegener; 2019 Nov; 14(1):39. PubMed ID: 31684998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
